Table 2.
SARS-Cov-2 diagnosis and clinical severity in propensity score-matched groups of PLWH based on antiretroviral therapy (ART) and results from Cox regression models that evaluated the effect of ART regimens on SARS-CoV-2 diagnosis and associated hospitalization
| TAF/FTC versus ABC/3TC | ||||||
|---|---|---|---|---|---|---|
| Totala | TAF/FTCa | ABC/3TCa,b | P valuec | uOR (95% CI) | aOR (95% CI) | |
| SARS-CoV-2 diagnosis | 0.256 | 0.92 (0.80–1.05) | 0.90 (0.78–1.04) | |||
| Positive | 848 (12.1) | 408 (11.6) | 440 (12.5) | |||
| Negative | 6176 (87.9) | 3104 (88.4) | 3072 (87.5) | |||
| Clinical severity | 0.838 | |||||
| Asymptomatic | 380 (44.8) | 186 (45.6) | 194 (44.1) | |||
| Symptomatic mild community management | 370 (43.6) | 172 (42.3) | 198 (45.0) | |||
| Hospitalizationd | 98 (11.6) | 50 (12.3) | 48 (10.9) | 1.04 (0.70–1.55) | 0.93 (0.60 -1.43) | |
| ICU admission | 4 (0.5) | 2 (0.5) | 2 (0.5) | |||
| Deathe | 17 (2.0) | 9 (2.2) | 8 (1.8) | |||
| TDF/FTC versus ABC/3TC | ||||||
| Total | TDF/FTC | ABC/3TCb | P valuec | uOR (95% CI) | aOR (95% CI) | |
| SARS-CoV-2 diagnosis | 0.021 | 0.74 (0.57–0.95) | 0.79 (0.60–1.04) | |||
| Positive | 369 (12.0) | 74 (9.6) | 295 (12.8) | |||
| Negative | 2704 (88.0) | 697 (90.4) | 2007 (87.2) | |||
| Clinical severity | 0.352 | |||||
| Asymptomatic | 172 (46.6) | 40 (54.1) | 132 (44.8) | |||
| Symptomatic mild community management | 170 (46.1) | 31 (41.9) | 139 (47.1) | |||
| Hospitalizationd | 27 (7.3) | 3 (4.1) | 24 (8.1) | 0.37 (0.11–1.24) | 0.51 (0.15–1.70) | |
| ICU admission | 2 (0.5) | 0 (0) | 2 (0.7) | |||
| Deathe | 3 (0.8) | 0 (0) | 3 (1.0) | |||
| TAF/FTC versus TDF/FTC | ||||||
| Total | TAF/FTCb | TDF/FTC | P valuec | uOR (95% CI) | aOR (95% CI) | |
| SARS-CoV-2 diagnosis | 0.012 | 0.72 (0.56–0.93) | 0.79 (0.60–1.04) | |||
| Positive | 377 (12.2) | 303 (13.1) | 74 (9.6) | |||
| Negative | 2703 (87.8) | 2007 (86.9) | 696 (90.4) | |||
| Clinical severity | 0.274 | |||||
| Asymptomatic | 190 (50.4) | 150 (49.5) | 40 (54.1) | |||
| Symptomatic mild community management | 150 (39.8) | 119 (39.3) | 31 (41.9) | |||
| Hospitalizationd | 37 (9.8) | 34 (11.2) | 3 (4.1) | 0.26 (0.08–0.86) | 0.33 (0.10–1.07) | |
| ICU admission | 3 (0.8) | 3 (1.0) | 0 (0) | |||
| Deathe | 6 (1.6) | 6 (2.0) | 0 (0) | |||
Adjusted model: Adjusted for country of origin, socioeconomic status, CD4 count (continuous variable), time in years on ART, CD4/CD8 ratio, diabetes, chronic kidney disease, chronic liver disease, and metabolic disease.
Abbreviations: TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; ABC/3TC, abacavir/lamivudine; ICU, intensive care unit, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; OR, odds ratio; uOR, unadjusted odds ratio; aOR, adjusted odds ratio; CI, confidence interval.
Data in this category is presented as n (%).
Reference group for odds ratios.
Numbers in bold indicate significant differences (P < 0.05).
Including ICU admissions.
Also included in hospitalized patients.